Recent large-scale trials disclosed at the 2025 IASLC World Conference on Lung Cancer demonstrate significant improvements in NSCLC therapy. Aumolertinib combined with chemotherapy showed superior progression-free survival in patients with EGFR and tumor suppressor gene mutations. Another bispecific antibody-drug conjugate, iza-bren, achieved a 100% response rate in EGFR-mutated NSCLC, signaling a breakthrough in precision oncology. Additional data from the COMPEL study and treatments like osimertinib combined with chemotherapy revealed enhanced survival and disease control, emphasizing the move toward combinatorial targeted regimens. These advancements promise improved outcomes and new therapeutic options for a prevalent lung cancer subset.